Filter Results
:
(623)
Show Results For
-
All HBS Web
(623)
- People (4)
- News (101)
- Research (417)
- Events (3)
- Multimedia (4)
- Faculty Publications (254)
Show Results For
-
All HBS Web
(623)
- People (4)
- News (101)
- Research (417)
- Events (3)
- Multimedia (4)
- Faculty Publications (254)
- 2010
- Working Paper
Boundary Spanning in a For-profit Research Lab: An Exploration of the Interface Between Commerce and Academe
By: Christopher C. Liu and Toby E. Stuart
In innovative industries, private-sector companies increasingly are participants in open communities of science and technology. To participate in the system of exchange in such communities, firms often publicly disclose what would otherwise remain private discoveries....
View Details
Keywords:
For-Profit Firms;
Higher Education;
Information Publishing;
Innovation and Invention;
Science-Based Business;
Social and Collaborative Networks;
Boundaries;
Pharmaceutical Industry;
Pharmaceutical Industry
Liu, Christopher C., and Toby E. Stuart. "Boundary Spanning in a For-profit Research Lab: An Exploration of the Interface Between Commerce and Academe." Harvard Business School Working Paper, No. 11-012, August 2010.
- January 2023
- Case
Cleave Therapeutics: Taking a Risk on Oncology Drug Discovery
By: Regina Herzlinger and Brian Walker
What should a successful executive (HBS Baker Scholar) assess as her next move as the CEO of a firm with a promising and yet uncertain new drug? Amy Burroughs’ mandate to successfully commercialize Cleave Therapeutics’ drug for a cancer with no current successful...
View Details
Keywords:
Product Development;
Leadership;
Health Testing and Trials;
Research and Development;
Risk and Uncertainty;
Financial Condition;
Partners and Partnerships;
Pharmaceutical Industry
Herzlinger, Regina, and Brian Walker. "Cleave Therapeutics: Taking a Risk on Oncology Drug Discovery." Harvard Business School Case 323-045, January 2023.
- January 2017
- Case
Danaher Corporation, 2007–2017
By: John R. Wells and Gabriel Ellsworth
On July 2, 2016, Danaher Corporation completed the spinoff of Fortive Corporation. The previous day, Danaher’s stock price had reached an all-time high. In 2015, Danaher had decided to split off its test and measurement, fuel and fleet management, and automation...
View Details
Keywords:
Danaher;
Fortive;
Larry Culp;
Beckman Coulter;
Pall;
Life Sciences;
Diagnostics;
Environmental Operations;
Water Management;
Dental;
Testing;
Measurement;
Fuel;
Fleet Management;
Automation;
Toolmaking;
Tools;
Disease Management;
Continuous Improvement;
Toyota Production System;
Divestiture;
Spinoffs;
Spin-off;
Networks;
Acquisition;
Mergers and Acquisitions;
Business Conglomerates;
Business Divisions;
Business Subsidiaries;
Business Units;
Business Growth and Maturation;
Business Model;
For-Profit Firms;
Joint Ventures;
Restructuring;
Engineering;
Chemicals;
Construction;
Machinery and Machining;
Profit;
Revenue;
Globalized Firms and Management;
Multinational Firms and Management;
Health;
Health Care and Treatment;
Health Disorders;
Medical Specialties;
Business History;
Job Cuts and Outsourcing;
Business or Company Management;
Growth and Development Strategy;
Management Analysis, Tools, and Techniques;
Management Practices and Processes;
Management Succession;
Management Systems;
Resource Allocation;
Market Entry and Exit;
Measurement and Metrics;
Logistics;
Business Processes;
Organizational Change and Adaptation;
Public Ownership;
Problems and Challenges;
Science;
Genetics;
Natural Environment;
Wastes and Waste Processing;
Science-Based Business;
Opportunities;
Strategy;
Adaptation;
Business Strategy;
Competition;
Competitive Strategy;
Competitive Advantage;
Consolidation;
Corporate Strategy;
Diversification;
Expansion;
Technology;
Software;
Technology Networks;
Technology Platform;
Value;
Valuation;
Pharmaceutical Industry;
Pharmaceutical Industry;
Pharmaceutical Industry;
Pharmaceutical Industry;
Pharmaceutical Industry;
Pharmaceutical Industry;
Pharmaceutical Industry;
Pharmaceutical Industry;
Pharmaceutical Industry;
Pharmaceutical Industry;
Pharmaceutical Industry;
Pharmaceutical Industry;
Pharmaceutical Industry;
Pharmaceutical Industry;
Pharmaceutical Industry;
Pharmaceutical Industry;
Pharmaceutical Industry;
Pharmaceutical Industry;
Pharmaceutical Industry;
Pharmaceutical Industry;
Pharmaceutical Industry;
Pharmaceutical Industry;
Pharmaceutical Industry;
United States;
District of Columbia
Wells, John R., and Gabriel Ellsworth. "Danaher Corporation, 2007–2017." Harvard Business School Case 717-464, January 2017.
- Web
Medical Devices | Baker Library | Bloomberg Center | Harvard Business School
Technavio Reports on a variety of global industries including technology, healthcare, retail, energy, aerospace, and automotive. Go To Database Companies Capital IQ https://www.library.hbs.edu/find/databases/capital-iq Data on public and...
View Details
- 22 Oct 2013
- First Look
First Look: October 22
expenditures on teammates lead to better performance in both sports teams in Canada and pharmaceutical sales teams in Belgium. These results suggest that a minor adjustment to employee bonuses-shifting the focus from the self to...
View Details
Keywords:
Sean Silverthorne
- 05 May 2023
- News
Fail Better
Subscribe on iTunes Subscribe on Spotify More Skydeck episodes Dan Morrell: Every year, HBS selects a small handful of outstanding alums to receive its most important honor, the Alumni Achievement Award. This year's recipients work in finance, politics, biopharma, and...
View Details
- 07 Oct 2014
- First Look
First Look: October 7
Results from a Natural Field Experiment in California By: Levine, David I., and Michael W. Toffel Abstract—For companies with strong internal occupational safety and health auditing programs, OSHA inspections might seem a formality that...
View Details
Keywords:
Sean Silverthorne
- 15 Jan 2013
- First Look
First Look: January 15
KnoopHarvard Business School Case 813-091 Amylin Pharmaceuticals brought two first-in-class diabetes drugs to market, Byetta and Symlin, in 2005, which were sold in over 80 countries with $650.7 million in sales by 2011. However, the...
View Details
Keywords:
Sean Silverthorne
- May 2012 (Revised August 2014)
- Case
McKesson
By: Regina E. Herzlinger and Natalie Kindred
McKesson, a large, diversified drug distribution and health care IT company, is considering development of new business offerings to help private practice physicians remain independent. The company, with $122 billion in 2010 revenues, just made its first foray into...
View Details
Keywords:
Health Care Industry;
Health Care Policy;
Organizational Transformations;
Health Services;
Health Care and Treatment;
Business Model;
Service Operations;
Change Management;
Corporate Strategy;
Information Technology;
Policy;
Pharmaceutical Industry;
Pharmaceutical Industry;
United States
Herzlinger, Regina E., and Natalie Kindred. "McKesson." Harvard Business School Case 312-002, May 2012. (Revised August 2014.)
- 24 Jan 2012
- First Look
First Look: Jan. 24
This chapter proposes a new lens to understand corruption, using internal records collected from firms that pay bribes. We examine widespread corruption in three industries in an Asian developing country: procurement, pharmaceutical...
View Details
Keywords:
Sean Silverthorne
- 06 Jun 2017
- First Look
First Look at New Research and Ideas: June 6, 2017
regulatory pathway, the biosimilars pathway, on the strategy of a major pharmaceutical firm that finds its largest product (60% of revenue) at risk. The case reviews the rationale for the pathway, the emerging biosimilars market entrants,...
View Details
Keywords:
Sean Silverthorne
- 04 Sep 2018
- First Look
New Research and Ideas, September 4, 2018
in talent clusters—a tactic Vodafone uses effectively. These three options aren’t mutually exclusive. Given the need to stay in touch with multiple clusters, companies may want to try them all. Each one involves substantial risks that...
View Details
Keywords:
Dina Gerdeman
- 05 May 2015
- First Look
First Look: May 5
merely distributed value in each era are explored. Although there is no framework yet for how leaders can create value for all stakeholders, we note that a key theme amongst the companies illustrated is that each was able to align...
View Details
Keywords:
Carmen Nobel
- 30 Aug 2016
- First Look
August 30, 2016
our propositions using empirical data from a large pharmaceutical firm encompassing 407 architectural components and 1,157 dependencies between them. We show that different components occupy different positions in the IT architecture and...
View Details
Keywords:
Carmen Nobel
- 06 Mar 2012
- First Look
First Look: March 6
century. It focuses especially on Beiersdorf, a pharmaceutical and skin care company in Germany. During World War I, the expropriation of its brands and trademarks revealed its vulnerability to political...
View Details
Keywords:
Sean Silverthorne
- 21 May 2013
- First Look
First Look: May 21
pharmaceutical sales teams in Belgium and sports teams in Canada. These results suggest that a minor adjustment to employee bonuses-shifting the focus from the self to others-can produce measurable benefits for employees and...
View Details
Keywords:
Sean Silverthorne
- 25 Apr 2005
- Research & Ideas
New Learning at American Home Products
pharmaceutical companies in 1984, American Home Products ranked first in sales and twenty-eighth in R&D expenditures as a percentage of sales.23 As the historian Williams Haynes noted, by the end of the...
View Details
- Profile
Janet Simpson Benvenuti
Caring for her aging parents led Janet Simpson Benvenuti (MBA 1985) to launch a company that helps other families find resources that are right for their own parents’ needs.
View Details
- 12 Dec 2022
- Research & Ideas
Buy-In from Black Patients Suffers When Drug Trials Don’t Include Them
ask them whether a drug will “work in people like me.” Beyond the health and financial ramifications of overlooking large population segments, the research offers a call to action for drugmakers at a time when companies face pressure to...
View Details
Richard L. Gelb
Gelb orchestrated Bristol-Myers' successful acquisition of Squibb creating the second largest pharmaceutical company in the world. In diversifying Bristol-Myers from a personal care View Details
Keywords:
Healthcare